6505--Acamprosate CA EC Tablets

SOL #: 36E79726R0021Pre-Solicitation

Overview

Buyer

Veterans Affairs
Veterans Affairs, Department Of
NAC PHARMACEUTICALS (36E797)
HINES, IL, 60141, United States

Place of Performance

Place of performance not available

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Apr 20, 2026
2
Response Deadline
May 6, 2026, 7:30 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The VA National Acquisition Center intends to issue a Request for Proposal (RFP) #36E79726R0021 for an unrestricted procurement of Acamprosate Calcium (CA) Enteric Coated (EC) Tablets. This contract will supply the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The solicitation is expected on or about May 7, 2026, with a tentative closing date of May 21, 2026.

Scope of Work

The requirement is for Acamprosate CA EC 333MG Tablets, supplied in 180-count bottles. Key specifications include:

  • Packaging: Unit of use packaging is mandatory. Bottles must have a minimum 120cc volume, a safety cap (convertible to non-safety), a minimum 5.75" circumference, and accommodate a 5.25" x 2" label with an additional 0.5" for barcode/expiration date/lot number.
  • Labeling: Offerors must state the exact drug name and possess a unique NDC number. The successful offeror's label with its unique NDC shall be the only label on the product, with VA labels adhering securely over it.
  • Distribution: Contracted items will be distributed through the VA's and DoD's respective Pharmaceutical Prime Vendor Programs.

Contract Details

  • Contract Type: One contract will be awarded.
  • Period of Performance: One base year plus four pre-priced one-year option periods.
  • Estimated Annual Usage: 33,661 bottles of 180-count tablets.
  • NAICS Code: 325412.

Submission & Evaluation

  • Solicitation Issuance: RFP #36E79726R0021 will be electronically issued in commercial item format (FAR Part 12) on or about May 7, 2026.
  • Response Date: Tentative closing date is May 21, 2026.
  • Submission Method: Offers must be submitted electronically via SAM.gov. No paper copies or telephone requests for solicitations will be accepted.
  • Offeror Requirements: Must provide the exact drug name (as it appears on the label) and have a unique NDC number.

Eligibility / Set-Aside

This is an unrestricted procurement. Award will be made to the responsible offeror capable of providing an uninterrupted source of supply.

Contact Information

For questions, contact Deb Fassl, Contract Specialist, via email at Deborah.Fassl@va.gov or phone at 708-786-5894. Interested offerors are advised to continuously monitor SAM.gov for any amendments or updates.

People

Points of Contact

Deb FasslContract SpecialistPRIMARY

Files

Files

Download

Versions

Version 1Viewing
Pre-Solicitation
Posted: Apr 20, 2026
6505--Acamprosate CA EC Tablets | GovScope